Stockwell Lynn 的 Form 4 申報
Drugs Made In America Acquisition II Corp.（DMII），2025/10/1 申報
- 申報編號
- 0001213900-25-094436
- 申報時間
- 2025/10/1
- 交易日
- 2025/9/26
- 申報延遲
- 5 天遲報
- 10b5-1 計畫
- 沒有勾選
這份申報列了 3 筆非衍生性交易、1 筆衍生性交易。交易後 5 天才申報，超過 2 個營業日的期限。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Stockwell LynnCIK 0001927032 | 董事、高階主管（CEO and Exe. Chair of Board）、持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Reflects 700,000 private units acquired by Drugs Made In America Acquisition II LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $7,000,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.
表 I 有 1 筆、表 II 有 1 筆交易的價格引用這則附註。
- F2
As of the Transaction Date, the sponsor transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.
表 I 有 1 筆交易的價格引用這則附註。
- F3
As of the Transaction Date, pursuant to share transfer agreements, the sponsor transferred an aggregate of 7,966,667 ordinary shares to a number of accredited investors for consideration ranging from no consideration to $1.50 per share.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.
表 II 有 1 筆交易的價格引用這則附註。